NL0.F GRAIL, Inc.

Healthcare Diagnostics & Research Frankfurt Exchange
111.95 EUR
Close of Nov 12, 2026
34.00 142.70
Market cap
EUR 5.03B
P/E
-
P/B
2.26x
ROE
-16.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NL0.F undervalued?

Graham number

The Graham number of GRAIL, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GRAIL, Inc. fundamental analysis

No fundamental analysis for GRAIL, Inc. yet.

GRAIL, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GRAIL, Inc.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing,…

Full company profile